DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 527
- 试验地点
- 22
- 主要终点
- Percentage of Eyes With Anterior Chamber Cell Grade 0
研究概览
简要总结
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
详细描述
This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
DEXYCU (dexamethasone intraocular suspension) 9%.
DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
干预措施: DEXYCU (dexamethasone intraocular suspension) 9%. (Drug)
结局指标
主要结局
Percentage of Eyes With Anterior Chamber Cell Grade 0
时间窗: Postoperative day 8
Of eyes with a record at postoperative day 8, percentage with anterior chamber cell grade 0. Cells in the anterior chamber of the eye are indicative of intraocular inflammation and are evaluated using a slit-lamp biomicroscope; a grade of 0 indicates that no inflammatory cells were visible in a 1 mm by 1 mm slit beam.
次要结局
未报告次要终点